Skip to main content

Table 2 Overall demographics

From: Impact of ferumoxytol vs gadolinium on 4D flow cardiovascular magnetic resonance measurements in small children with congenital heart disease

 

Ferumoxytol (n = 21)

Gadolinium (n = 23)

p value

Age (years)

2.1 ± 1.6

2.3 ± 1.9

0.841

Male sex

9 (43%)

13 (57%)

0.377

Height (cm)

81.8 ± 19.1

84.0 ± 18.3

0.706

Weight (kg)

11.5 ± 5.1

12.2 ± 4.8

0.599

BSA (m2)

0.5 ± 0.2

0.52 ± 0.2

0.667

Great vessel diameter (mm)

16.3 ± 5.0

15.7 ± 5.9

0.575

Branch pulmonary arteries (mm)

9.0 ± 3.1

9.5 ± 2.7

0.267

Pulmonary vein diameter (mm)

7.2 ± 1.6

7.6 ± 2.0

0.889

Caval diameter (mm)

12.7 ± 3.9

10.7 ± 3.8

0.115

Diagnoses

 Single ventricle patients

5 (24%)

5 (22%)

0.874

 Conotruncal anomalies

7 (33%)

13 (56%)

0.129

 Anomalous systemic or pulmonary venous drainage

6 (29%)

3 (13%)

0.211

 Septal defects and AV valve anomalies

3 (14%)

2 (9%)

0.570

Study indication

 Eval anatomy, function, chamber size, Qp:Qs

10 (48%)

10 (43%)

0.789

 Eval outflow tract obstruction/regurgitation

1 (4%)

1 (4%)

0.949

 Eval branch pa stenosis/flow differential

5 (24%)

8 (35%)

0.437

 Pre-Glenn/Pre-Fontan

5 (24%)

4 (18%)

0.608

Use of anesthesia

 Moderate sedation or feed and bundle

7 (33%)

12 (52%)

0.217

 General anesthesia—ventilated

14 (67%)

11 (48%)

0.217

Resolution 4D (mm)

 1.30 × 1.25 × 1.25

15 (71%)

3 (13%)

< 0.001

 1.80 × 1.75 × 1.75

6 (29%)

20 (87%)

< 0.001

  1. Forty-four CMR studies from patients < 20 kg with congenital heart disease, 21 were performed with ferumoxytol and 23 with gadolinium. 10 were single ventricle patients, with 5 in the ferumoxytol cohort and 5 in the gadolinium cohort